TMIGD2 and leukemia: We also demonstrated that knockdown of TMIGD2 using shRNA or targeting TMIGD2 with mAbs significantly decreased colony-forming capacity of LSCs and effectively reduced leukemia burden in PDX models, highlighting TMIGD2 as a novel therapeutic target for AML treatment.